ES2100135T3 - Combinacion sinergica de una sustancia con efecto inhibidor de la secrecion de acido gastrico y un antibiotico degradable por los acidos. - Google Patents

Combinacion sinergica de una sustancia con efecto inhibidor de la secrecion de acido gastrico y un antibiotico degradable por los acidos.

Info

Publication number
ES2100135T3
ES2100135T3 ES93912028T ES93912028T ES2100135T3 ES 2100135 T3 ES2100135 T3 ES 2100135T3 ES 93912028 T ES93912028 T ES 93912028T ES 93912028 T ES93912028 T ES 93912028T ES 2100135 T3 ES2100135 T3 ES 2100135T3
Authority
ES
Spain
Prior art keywords
materials
degradable
acids
substance
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93912028T
Other languages
English (en)
Spanish (es)
Other versions
ES2100135T1 (es
Inventor
Arne Torsten Eek
Sven Erik Sjostrand
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26661401&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2100135(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from SE9201297A external-priority patent/SE9201297D0/xx
Priority claimed from SE9300029A external-priority patent/SE9300029D0/xx
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of ES2100135T1 publication Critical patent/ES2100135T1/es
Application granted granted Critical
Publication of ES2100135T3 publication Critical patent/ES2100135T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/04—Surgical instruments, devices or methods for suturing wounds; Holders or packages for needles or suture materials
    • A61B17/0469—Suturing instruments for use in minimally invasive surgery, e.g. endoscopic surgery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/04—Surgical instruments, devices or methods for suturing wounds; Holders or packages for needles or suture materials
    • A61B17/06—Needles ; Sutures; Needle-suture combinations; Holders or packages for needles or suture materials
    • A61B17/06066—Needles, e.g. needle tip configurations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/34—Trocars; Puncturing needles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/30—Joints
    • A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
    • A61F2002/30003—Material related properties of the prosthesis or of a coating on the prosthesis
    • A61F2002/3006—Properties of materials and coating materials
    • A61F2002/30092—Properties of materials and coating materials using shape memory or superelastic materials, e.g. nitinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2210/0014—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof using shape memory or superelastic materials, e.g. nitinol
    • A61F2210/0023—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof using shape memory or superelastic materials, e.g. nitinol operated at different temperatures whilst inside or touching the human body, heated or cooled by external energy source or cold supply
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2210/0014—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof using shape memory or superelastic materials, e.g. nitinol
    • A61F2210/0023—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof using shape memory or superelastic materials, e.g. nitinol operated at different temperatures whilst inside or touching the human body, heated or cooled by external energy source or cold supply
    • A61F2210/0047—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof using shape memory or superelastic materials, e.g. nitinol operated at different temperatures whilst inside or touching the human body, heated or cooled by external energy source or cold supply heated by light

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES93912028T 1992-04-24 1993-04-20 Combinacion sinergica de una sustancia con efecto inhibidor de la secrecion de acido gastrico y un antibiotico degradable por los acidos. Expired - Lifetime ES2100135T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9201297A SE9201297D0 (sv) 1992-04-24 1992-04-24 Synergistic combination
SE9300029A SE9300029D0 (sv) 1993-01-08 1993-01-08 Synergistic combination ii

Publications (2)

Publication Number Publication Date
ES2100135T1 ES2100135T1 (es) 1997-06-16
ES2100135T3 true ES2100135T3 (es) 2000-11-16

Family

ID=26661401

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93912028T Expired - Lifetime ES2100135T3 (es) 1992-04-24 1993-04-20 Combinacion sinergica de una sustancia con efecto inhibidor de la secrecion de acido gastrico y un antibiotico degradable por los acidos.

Country Status (38)

Country Link
US (3) US5599794A (Direct)
EP (2) EP0956857A3 (Direct)
JP (1) JPH07505901A (Direct)
KR (1) KR100340165B1 (Direct)
CN (1) CN1041798C (Direct)
AP (1) AP466A (Direct)
AT (1) ATE194286T1 (Direct)
AU (1) AU669903B2 (Direct)
CA (1) CA2133762C (Direct)
CZ (1) CZ291201B6 (Direct)
DE (2) DE69328967T2 (Direct)
DK (1) DK0637241T3 (Direct)
DZ (1) DZ1683A1 (Direct)
EE (1) EE03149B1 (Direct)
ES (1) ES2100135T3 (Direct)
FI (1) FI944953L (Direct)
GR (2) GR970300011T1 (Direct)
HR (1) HRP930755B1 (Direct)
HU (1) HUT71225A (Direct)
IL (1) IL105155A (Direct)
IS (1) IS3990A (Direct)
LV (1) LV12625B (Direct)
MA (1) MA22878A1 (Direct)
MY (1) MY121189A (Direct)
NO (1) NO314288B1 (Direct)
NZ (1) NZ252759A (Direct)
PL (1) PL173485B1 (Direct)
PT (1) PT637241E (Direct)
RO (1) RO115780B1 (Direct)
RU (1) RU2143899C1 (Direct)
SG (1) SG52485A1 (Direct)
SI (1) SI9300219B (Direct)
SK (1) SK282420B6 (Direct)
TN (1) TNSN93040A1 (Direct)
TW (1) TW276996B (Direct)
UA (1) UA43830C2 (Direct)
WO (1) WO1993021920A1 (Direct)
YU (1) YU49091B (Direct)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW420610B (en) * 1994-04-07 2001-02-01 Pfizer A pharmaceutical composition for treating a H. pylori infection or gastric or duodenal ulcers
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
US6132768A (en) * 1995-07-05 2000-10-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for reversible proton pump inhibitors
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
CN1061232C (zh) * 1996-04-12 2001-01-31 马理国 一种治疗胃炎、溃疡的药物组合物
SI9700186B (sl) 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin
PT1003554E (pt) * 1997-07-25 2005-03-31 Altana Pharma Ag Inibidor da bomba de protoes em combinacao terapeutica com substancias antibacterianas
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6733778B1 (en) * 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6117868A (en) * 1998-09-16 2000-09-12 Ed. Geistlich Sohne Ag Fur Chemische Industrie Treatment of gastrointestinal ulcers or gastritis caused by microbial infection
AU781133B2 (en) * 1999-02-26 2005-05-05 Nicox S.A. Nitrosated and nitrosylated proton pump inhibitors, compositions and methods of use
US6852739B1 (en) 1999-02-26 2005-02-08 Nitromed Inc. Methods using proton pump inhibitors and nitric oxide donors
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
US6316020B1 (en) * 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US6312723B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Pharmaceutical unit dosage form
US6780880B1 (en) 1999-08-26 2004-08-24 Robert R. Whittle FT-Raman spectroscopic measurement
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6262085B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6326384B1 (en) 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
US6262086B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Pharmaceutical unit dosage form
US6312712B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Method of improving bioavailability
US6268385B1 (en) 1999-08-26 2001-07-31 Robert R. Whittle Dry blend pharmaceutical formulations
US7365047B1 (en) * 1999-09-28 2008-04-29 The Regents Of The University Of California Use of pentagastrin to inhibit gastric acid secretion or as a diuretic
US20020004502A1 (en) * 2000-01-05 2002-01-10 Redmond H. Paul Treatment of inflammatory bowel disease
US6787342B2 (en) 2000-02-16 2004-09-07 Merial Limited Paste formulations
SK13722002A3 (sk) * 2000-02-29 2003-08-05 Teva Pharmaceutical Industries Ltd. Spôsob prípravy klaritromycínu a klaritromycínového medziproduktu, v podstate prostého oxímu a farmaceutický prostriedok, ktorý ho obsahuje
WO2001066117A1 (en) * 2000-03-09 2001-09-13 Ian Andrew Whitcroft Treatment of inflammatory dermatoses comprising erythromycin or clarythromycin metronidazole and a gastrointestinal hydrogen pump inhibitor
EP1133987A1 (en) * 2000-03-09 2001-09-19 Ian Whitcroft Treatment of inflammatory dermatoses with combinations of erythromycin or clarythromycin, metronidazole and a hydrogen pump inhibitor
DE60138876D1 (de) * 2000-03-28 2009-07-16 Sandoz Ag Geschmackmaskierte granulierte teilchen
SE0002476D0 (sv) 2000-06-30 2000-06-30 Astrazeneca Ab New compounds
US6544556B1 (en) 2000-09-11 2003-04-08 Andrx Corporation Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
WO2002026210A2 (en) * 2000-09-29 2002-04-04 Geneva Pharmaceuticals Inc. Proton pump inhibitor formulation
SE0103695D0 (sv) 2001-11-07 2001-11-07 Thomas Boren A novel non-antibiotic strategy against OGIP infections based on a cereal product
AU2002365936A1 (en) * 2001-11-16 2003-09-02 Eisai Co. Ltd Compositions and methods to treat gastrointestinal disorders
JP2005521662A (ja) * 2002-01-25 2005-07-21 サンタラス インコーポレイティッド プロトンポンプ阻害剤の経粘膜送達
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
US7211590B2 (en) * 2002-08-01 2007-05-01 Nitromed, Inc. Nitrosated proton pump inhibitors, compositions and methods of use
JP2006516574A (ja) * 2003-02-05 2006-07-06 テバ ファーマシューティカル インダストリーズ リミティド ランソプラゾール安定化方法
JP2006518751A (ja) * 2003-02-20 2006-08-17 サンタラス インコーポレイティッド 胃酸の急速かつ持続的な抑制のための新規製剤、オメプラゾール制酸剤複合体−即時放出物
US20040185092A1 (en) * 2003-03-18 2004-09-23 Yih Ming Hsiao Pharmaceutical preparations of omeprazole and/or clarithromycin for oral use
MXPA06000524A (es) * 2003-07-18 2006-08-11 Santarus Inc Formulacion farmaceutica y metodo para tratar desordenes gastrointestinales provocados por acido.
MXPA06000529A (es) * 2003-07-18 2006-08-11 Santarus Inc Formulaciones farmaceuticas utiles para inhibir la secrecion de acido y metodos para elaborarlas y utilizarlas.
US8993599B2 (en) * 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) * 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) * 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20060194748A1 (en) * 2005-02-28 2006-08-31 National University Corporation Nagoya University Methods for treating disorders induced by H. pylori infections and pharmaceutical compositions for the same
WO2007070164A1 (en) * 2005-10-19 2007-06-21 The Curators Of The University Of Missouri Pharmaceutical composition comprising a proton pump inhibitor, a buffering agent and an anti-h. pylori active substance and methods of using same
US20070141151A1 (en) * 2005-12-20 2007-06-21 Silver David I Lansoprazole orally disintegrating tablets
CA2665226C (en) 2006-10-05 2014-05-13 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
AU2007317561A1 (en) 2006-10-27 2008-05-15 The Curators Of The University Of Missouri Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US10869690B2 (en) * 2017-06-29 2020-12-22 Ethicon Llc Trocar obturator with transverse needle ports
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85472A (en) * 1987-03-09 1991-06-30 Procter & Gamble Pharmaceutical compositions for treating gastrointestinal disorders
JP2694361B2 (ja) * 1989-02-09 1997-12-24 アストラ アクチエボラグ 抗菌剤
DK0382489T3 (da) * 1989-02-10 1995-01-16 Takeda Chemical Industries Ltd Monoklonalt anti-humant papillomvirusantistof, hybridomcelle, der producerer dette, samt fremgangsmåde til fremstilling deraf
GB9018603D0 (en) * 1990-08-24 1990-10-10 Smith Kline French Lab Compositions
DE59109225D1 (de) * 1990-09-14 2002-01-17 Byk Gulden Lomberg Chem Fab Verwendung von pyridylmethylsulfinyl-1h-benzimidazol derivaten zur behandlung durch helicobacter verursachter erkrankungen

Also Published As

Publication number Publication date
IS3990A (is) 1993-10-25
EE03149B1 (et) 1999-02-15
EP0956857A2 (en) 1999-11-17
NO944010D0 (no) 1994-10-21
LV12625B (en) 2001-07-20
FI944953A7 (fi) 1994-10-21
CZ259394A3 (en) 1995-08-16
AU4273793A (en) 1993-11-29
DZ1683A1 (fr) 2002-02-17
RU2143899C1 (ru) 2000-01-10
YU49091B (sh) 2003-12-31
IL105155A0 (en) 1993-07-08
HUT71225A (en) 1995-11-28
EP0637241A1 (en) 1995-02-08
US5633244A (en) 1997-05-27
IL105155A (en) 1999-05-09
WO1993021920A1 (en) 1993-11-11
MY121189A (en) 2006-01-28
NO314288B1 (no) 2003-03-03
HRP930755A2 (en) 1994-10-31
GR970300011T1 (en) 1997-05-31
DE69328967D1 (de) 2000-08-10
EP0637241B1 (en) 2000-07-05
CZ291201B6 (cs) 2003-01-15
FI944953A0 (fi) 1994-10-21
SK282420B6 (sk) 2002-01-07
KR100340165B1 (ko) 2002-10-04
YU27593A (sh) 1996-10-09
ATE194286T1 (de) 2000-07-15
CA2133762A1 (en) 1993-11-11
AP9300518A0 (en) 1993-04-30
CN1041798C (zh) 1999-01-27
TNSN93040A1 (fr) 1994-03-17
HK1008296A1 (en) 1999-05-07
CA2133762C (en) 2000-08-01
EP0956857A3 (en) 2003-11-26
HU9403069D0 (en) 1994-12-28
LV12625A (en) 2001-03-20
RO115780B1 (ro) 2000-06-30
AP466A (en) 1996-03-05
NO944010L (no) 1994-10-21
DK0637241T3 (da) 2000-09-11
DE637241T1 (de) 1997-09-11
HRP930755B1 (en) 2001-04-30
PL173485B1 (pl) 1998-03-31
CN1081614A (zh) 1994-02-09
MA22878A1 (fr) 1993-12-31
NZ252759A (en) 1996-12-20
SK127594A3 (en) 1995-04-12
PT637241E (pt) 2000-10-31
JPH07505901A (ja) 1995-06-29
SG52485A1 (en) 1998-09-28
UA43830C2 (uk) 2002-01-15
TW276996B (Direct) 1996-06-01
DE69328967T2 (de) 2000-12-07
US5599794A (en) 1997-02-04
AU669903B2 (en) 1996-06-27
FI944953L (fi) 1994-10-21
GR3034470T3 (en) 2000-12-29
ES2100135T1 (es) 1997-06-16
US5629305A (en) 1997-05-13
SI9300219A (sl) 1993-12-31
SI9300219B (en) 2001-12-31

Similar Documents

Publication Publication Date Title
ES2100135T3 (es) Combinacion sinergica de una sustancia con efecto inhibidor de la secrecion de acido gastrico y un antibiotico degradable por los acidos.
ES2107648T3 (es) Acidos hidroxamicos substituidos con arilsulfonamido.
BR0017013A (pt) Composições de antibiótico azalìdeo
AR018042A1 (es) Uso de compuestos de quinolina para la preparacion de medicamentos para el tratamiento de infecciones bacterianas en mamiferos, particularmenteen el hombre, composiciones farmaceuticas formuladas con dichos compuestos y procedimiento de preparacion de dichos compuestos de quinolina
AR028833A1 (es) Compuestos inhibidores de metaloproteasas, composiciones farmaceuticas, uso para la manufactura de medicamentos, metodo de tratamiento y procedimiento para su preparacion
UY25330A1 (es) Nuevos macrólidos
UY23991A1 (es) PROCEDIMIENTO PARA LA PREPARACION DE LA FORMA TRIHIDRATADA DEL (2R,3S)-3-TERT-BUTOXICARBONILAMINO-2-HIDROXI-3-FENILPROPIONATO DE 4-ACETOXI-2-ALFA-BENZOILOXI-5ß,20-EPOXI-1-7ß,10ß-TRIHIDROXI-9-OXO-TAX-11-EN-ILO-13- ALFA POR CRISTALIZACION A PARTIR DE UNA SOLUCION HIDRO-ALCOHOLICA
ES2066045T3 (es) Derivados de acido poliaspartico como medio de recubrimiento para medicamentos y alimentos.
AR031975A1 (es) Compuestos analogos de (1r,cis)-4-(6-amino-9h-purin-9-il) -2-ciclopenteno-1-metanol, proceso para su preparacion, su uso en el tratamiento de infecciones virales, y envase que los contiene
AR026064A1 (es) Compuestos de oxabispidina, formulacion farmaceutica, uso de estos compuestos para la manufactura de medicamentos, proceso para la preparacion de estos compuestos, e intermediarios.
ECSP093680A (es) Proceso para derivados del acido fenilacetico
AR037654A1 (es) Base libre de clindamicina sustancialmente cristalina, sustancia droga, composicion farmaceutica y su uso en la fabricacion de un medicamento y proceso para preparar dicha base libre cristalina de clindamicina
CY1116044T1 (el) Μεθοδος για την παρασκευη δισκιων που περιεχουν s-αδενοσυλομεθειονινη
AR025052A1 (es) Derivados de 2-dialquilaminoalquilbifenilo sustituidos, procedimiento para su preparacion, medicamentos que contienen estos compuestos y el uso de estoscompuestos para la preparacion de medicamentos.
CO4960655A1 (es) Nueva composicion y su uso
DE69813496D1 (de) Zyklodextrin-Zusammensetzung enthaltend ein Avermectin- oder ein Milbemycin-Derivat
EP1834670A3 (en) Anthelmintic compositions containing combinations of avermectins or milbemycins with bis-aryl compounds
AR030662A1 (es) Beta-tio-alfa-aminoacidos, procedimiento para su fabricacion, medicamentos que contienen estos compuestos y el uso de los tioaminoacidos para la preparacion de medicamentos
DE60118132D1 (de) Anthelmintika
MX9302034A (es) Bencidazoles, medicamentos que contienen estos compuestos y procedimientos para su preparacion.
AR035553A1 (es) Formas cristalinas de melagatran, proceso para su produccion, formulacion farmaceutica, y uso de este compuesto en la elaboracion de medicamentos.
ES2176758T3 (es) Procedimiento para la preparacion de 4-ciona-1,2,3-triazxoles.
BR0012792A (pt) Composições antibacterianas de ácido de lúpulo, e método para reduzir o número de bactérias gram-positivas em produtos alimentìcios e não alimentìcios
PE20010287A1 (es) Sal difosfato de un derivado de 4"-sustituido-9-desoxo-9a-aza-9a-homoeritromicina y su composicion farmaceutica
JO1768B1 (en) A synergistic formula with an inhibitory effect of gastric acid secretion and an acid-degradable antibiotic

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 637241

Country of ref document: ES